Peng Peng

TransThera Sciences (Nanjing), Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

38

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Tinengotinib for Adult Patients with Advanced or Metastatic Cholangiocarcinoma: A Multicenter, Open-Label Phase 2 Trial

Number of pages: 49 Posted: 25 Mar 2025
University of Texas at Houston - MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center - Department of Medicine, University of Chicago - Division of Biological Sciences, Sarah Cannon Research Institute, City of Hope - Comprehensive Cancer Center, University of Wisconsin-Madison, University of Michigan at Ann Arbor, Mayo Clinic College of Medicine and Science, Rocky Mountain Cancer Centers, Methodist Dallas Medical Center, Texas Oncology, Comprehensive Cancer Centers of Nevada, TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc., TransThera Sciences (Nanjing), Inc. and University Hospitals Cleveland Medical Center, Seidman Cancer Center
Downloads 38 (950,723)

Abstract:

Loading...

cholangiocarcinoma, intrahepatic, FGFR, FGFR2, FGFR inhibotor